Nuevolution announces the publication of a second scientific article from the collaboration with Nobel Laureate Dr. Robert J. Lefkowitz

Stockholm, 17 May 2018. Nuevolution AB (publ) (NUE.ST) today announced the publication of the scientific article entitled "Small Molecule Positive Allosteric Modulators of the β2-Adrenergic Receptor Isolated from DNA Encoded Libraries in the journal Molecular Pharmacology.

The new article presents further exciting work from the ongoing collaboration between Nuevolution and the group of Nobel Laureate Dr. Robert J. Lefkowitz at Duke University involving the screening of Nuevolution compound libraries against an important class of targets named GPCRs. The new publication extends our previous joint publication from 2017 now showing the identification of compounds capable of stimulating signaling across a cell membrane by a key GPCR.

We have a very strong collaboration with the world-leading group of Dr. Lefkowitz’ and we are happy to see yet another great publication from this joint work and to showcase the capability of our technology on GPCR receptors” said Thomas Franch, CSO of Nuevolution and continued “The two joint publications identifying both negative and positive allosteric GPCR modulators really open up novel future opportunities for identifying drug candidates against many GPCR’s relevant for human diseases”.

For more information, please contact:

Johnny Stilou, Director of investor relations

Phone: +45 8877 5973


Thomas Franch, CSO

Phone: +45 7020 0987


About Chemetics™

The Nuevolution Chemetics™ technology comprises proprietary methods enabling DNA-encoding of fragments and combinatorial chemistry libraries for fast and cost efficient screening of disease targets. Nuevolution annually produces 4-8 Chemetics™ libraries comprising millions to multi billions of compounds per library. For further details about Chemetics™, please visit:

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information was sent for publication, through the agency of the contact persons set out above, on Thursday 17 May 2018 at 14:00 CET.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas


Documents & Links